Blue Trust Inc. Purchases 6,667 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

Blue Trust Inc. increased its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 550.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,879 shares of the company’s stock after buying an additional 6,667 shares during the quarter. Blue Trust Inc.’s holdings in Roivant Sciences were worth $91,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Gladius Capital Management LP bought a new stake in Roivant Sciences in the 3rd quarter worth $35,000. US Bancorp DE grew its stake in shares of Roivant Sciences by 146.5% in the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after purchasing an additional 1,948 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after purchasing an additional 1,288 shares during the last quarter. Quarry LP increased its holdings in Roivant Sciences by 50.0% during the 3rd quarter. Quarry LP now owns 7,500 shares of the company’s stock valued at $87,000 after purchasing an additional 2,500 shares during the period. Finally, ORG Wealth Partners LLC bought a new position in Roivant Sciences during the 3rd quarter valued at approximately $113,000. 64.76% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, COO Eric Venker sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $11.28, for a total value of $1,128,000.00. Following the sale, the chief operating officer now directly owns 732,294 shares of the company’s stock, valued at $8,260,276.32. The trade was a 12.01 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Sciences Ltd. Roivant acquired 16,845,010 shares of Roivant Sciences stock in a transaction that occurred on Monday, January 13th. The shares were bought at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the transaction, the director now owns 96,650,341 shares in the company, valued at $1,933,006,820. This represents a 21.11 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 1,942,629 shares of company stock worth $23,034,486. 7.90% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research report on Wednesday, November 13th. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a report on Thursday, January 30th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $17.93.

Roivant Sciences Stock Up 0.2 %

ROIV opened at $10.89 on Friday. The stock has a market cap of $7.93 billion, a PE ratio of 1.93 and a beta of 1.25. The business has a 50 day moving average of $11.55 and a 200-day moving average of $11.59. Roivant Sciences Ltd. has a 52 week low of $9.76 and a 52 week high of $13.06.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.